
CBG Protected Memory in a Schizophrenia Model. The Reason It Worked Wasn’t the One Scientists Expected.
Repeated CBG treatment prevented a long-term recognition memory deficit in male rats given MK-801, a compound used to model the cognitive impairments seen in schizophrenia. CBG did not restore the BDNF protein levels MK-801 had lowered, but it raised TrkB messenger RNA in the medial prefrontal cortex, pointing to a mechanism the researchers had not expected.











